GoAI
Get started
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc.

ORMP

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$4.81

+$0.02 · +0.42%

Aug 21, 4:00 PM ET

Pre-market

$4.71

−$0.10 · -2.08%

Aug 24, 4:01 AM ET

ORMP company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

71

Undervalued

Momentum

56

Neutral

Sentiment

64

Bullish

Risk resilience

44

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Nadav Kidron
Listed since
May 1, 2007
Employees
13

Market position

Day range

Current $4.81

52-week range

Current $4.81

Open
$4.805
Previous close
$4.79
Volume
126.13K
0.49× average
Average volume
259.21K
Average daily volume
Market cap
196.85M USD
Beta
1.16
Market reference 1
50-day average
$4.263
+12.83% above average
200-day average
$3.6018
+33.54% above average

Financials

Financial snapshot

Latest / TTM

Financial health

Altman Z-score
4.76
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends3673%1791%-91%-1972%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2025: 0.65%Operating margin, FY2021: -896.15%Operating margin, FY2022: -1501.96%Operating margin, FY2023: -1176.79%Operating margin, FY2025: -754.40%Net margin, FY2021: -822.72%Net margin, FY2022: -1397.11%Net margin, FY2023: 412.31%Net margin, FY2025: 3202.50%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2025 0.65%. Operating margin FY2021 -896.15%. Operating margin FY2022 -1501.96%. Operating margin FY2023 -1176.79%. Operating margin FY2025 -754.40%. Net margin FY2021 -822.72%. Net margin FY2022 -1397.11%. Net margin FY2023 412.31%. Net margin FY2025 3202.50%.

Income trends

Revenue

2M USD+49.25%

Operating income

−15.09M USD-18.05%

Net income

64.05M USD+83.15M USD
Income trends across reported periods74.51M USD32.66M USD−9.2M USD−51.06M USDRevenue, FY2021: 2.7M USDRevenue, FY2022: 2.7M USDRevenue, FY2023: 1.34M USDRevenue, FY2025: 2M USDOperating income, FY2021: −24.22M USDOperating income, FY2022: −40.6M USDOperating income, FY2023: −15.77M USDOperating income, FY2024: −12.78M USDOperating income, FY2025: −15.09M USDNet income, FY2021: −22.24M USDNet income, FY2022: −37.76M USDNet income, FY2023: 5.53M USDNet income, FY2024: −19.1M USDNet income, FY2025: 64.05M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 2.7M USD. Revenue FY2022 2.7M USD. Revenue FY2023 1.34M USD. Revenue FY2025 2M USD. Operating income FY2021 −24.22M USD. Operating income FY2022 −40.6M USD. Operating income FY2023 −15.77M USD. Operating income FY2024 −12.78M USD. Operating income FY2025 −15.09M USD. Net income FY2021 −22.24M USD. Net income FY2022 −37.76M USD. Net income FY2023 5.53M USD. Net income FY2024 −19.1M USD. Net income FY2025 64.05M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue2M USD—1.34M USD2.7M USD2.7M USD
Cost of goods sold1.99M USD193K USD———
Gross profit13K USD−193K USD1.34M USD2.7M USD2.7M USD
Research and development6.38M USD6.32M USD8.97M USD27.64M USD20.99M USD
Selling, general, and administrative8.72M USD6.46M USD8.14M USD15.66M USD5.94M USD
Operating expenses15.1M USD12.78M USD17.11M USD43.3M USD26.93M USD
Interest income2.37M USD—8.03M USD3.57M USD347K USD
Interest expense—853K USD3.58M USD—6K USD
Depreciation and amortization121K USD193K USD196K USD3.62M USD77K USD
Operating income−15.09M USD−12.78M USD−15.77M USD−40.6M USD−24.22M USD
Net income64.05M USD−19.1M USD5.53M USD−37.76M USD−22.24M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
1.5
FY2025
Latest fiscal-year revenue
2M USD
FY2025

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend1.750.76-0.23-1.22FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend2.97M1.89M810.9K-270.3KFY21FY22FY23FY24FY25

ORMP news

gurufocus.com

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation

Read source
prnewswire.com

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million) Scilex (NASDAQ: SCLX) Loan Substantially Repaid Total Cash and Assets Build to Approximately $270 Million (as of March 31, 2026, after the…

Read source
prnewswire.com

Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes

NEW YORK, June 17, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it is set to join the U.S. small cap Russell 2000® and broad-market Russell 3000®…

Read source

Corporate actions

Corporate action history

Stock split

Effective Jan 23, 2013

1:12

Stock split

Effective Jun 14, 2004

33:10

ORMP peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ORMP

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
2.99M
Weight
0.00%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
1.52M
Weight
0.01%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
775.83K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
573.2K
Weight
0.04%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF logoGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC
Market value
275.64K
Weight
0.03%
AUM
1.08B USD
Expense ratio
0.20%
Price / 1D
$91.32+0.82%
Avantis U.S. Small Cap Equity ETF logoAvantis U.S. Small Cap Equity ETFAVSC
Market value
266.43K
Weight
0.01%
AUM
3.16B USD
Expense ratio
0.25%
Price / 1D
$73.84+0.70%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
194.72K
Weight
0.00%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$83.02+0.73%
Dimensional - US Core Equity 2 ETF logoDimensional - US Core Equity 2 ETFDFAC
Market value
175.74K
Weight
0.00%
AUM
49.31B USD
Expense ratio
0.17%
Price / 1D
$45.61+0.46%

Continue in GoAI

Research ORMP

research.disclaimer